Calgary, Alberta – TheNewswire - July 9, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce that it has completed training of the clinical team at its first study site in Mexico City.  This training is in preparation for the upcoming first-in-human (FIH) clinical study of the Ocumetics accommodating intraocular lens (the “Ocumetics Lens”).

Dean Burns, CEO of Ocumetics Technology Corp., emphasized the importance of this milestone, stating, “We are excited to announce the finalization of our site training protocol - a vital step in ensuring the successful launch of our first-in-human study.  Meticulous training of surgeons and staff at the clinical study site is key to achievement of optimal outcomes and the highest standard of care.”  

This training marks a critical milestone in Ocumetics’ 18-year journey toward regulatory approval of a transformative accommodating intraocular lens technology intended to restore vision for patients undergoing cataract extraction.  The training program is designed to ensure that all participating staff members are equipped with the specialized skills and knowledge necessary to implant the Ocumetics Lens with precision and safety.

The Ocumetics Lens is designed to restore the ability to see both distant and near objects clearly without glasses following cataract surgery.  The training program covers every phase of the clinical trial process, including pre-operative assessment, lens handling, surgical technique, and post-operative care.  Using proven training methods, the curriculum ensures successful execution of the first clinical study of this novel technology.

With clinical team training completed, and ethics committee approval pending, Ocumetics is poised to launch its historic FIH trial—an essential step toward clinical validation and eventual regulatory approval to market the Ocumetics Lens.

  

About Ocumetics

Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is a Canadian research and product development company that is dedicated to developing advanced vision correction solutions that enhance the quality of life for patients.  Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies.

Ocumetics is in the preclinical study phase of a game-changing technology for the ophthalmic industry.  Ocumetics has developed an intraocular lens that fits within the natural lens compartment of the eye, potentially to eliminate the need for corrective lenses.  It is designed to allow the eye’s natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the help of glasses or contact lenses.  

 

FOR FURTHER INFORMATION, PLEASE CONTACT:

 

Dean Burns                                Roger Jewett

President and Chief Executive Officer        Chief Financial Officer

(817) 874-7564                                roger.jewett@ocumetics.com

 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain “forward-looking statements” under applicable Canadian securities legislation.  Forward-looking statements include, but are not limited to, statements with respect to the commencement, timing and scope of the research and development to be conducted by the Corporation mentioned above.  Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include but are not limited to: operational matters, historical trends, current conditions and expected future developments, access to financing as well as other considerations that are believed to be appropriate in the circumstances.  There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.  The Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.